These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 9812180)

  • 41. Ciprofloxacin pharmacokinetics in young cystic fibrosis patients after repeated oral doses.
    Odoul F; Le Guellec C; Giraut C; de Gialluly C; Marchand S; Paintaud G; Saux MC; Rolland JC; Autret-Leca E
    Therapie; 2001; 56(5):519-24. PubMed ID: 11806288
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Small intestinal glucose absorption in cystic fibrosis: a study in human and transgenic DeltaF508 cystic fibrosis mouse tissues.
    Hardcastle J; Harwood MD; Taylor CJ
    J Pharm Pharmacol; 2004 Mar; 56(3):329-38. PubMed ID: 15025858
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacokinetics of gyrase inhibitors, Part 2: Renal and hepatic elimination pathways and drug interactions.
    Sörgel F; Kinzig M
    Am J Med; 1993 Mar; 94(3A):56S-69S. PubMed ID: 8383921
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Lean body mass as a predictor of drug dosage. Implications for drug therapy.
    Morgan DJ; Bray KM
    Clin Pharmacokinet; 1994 Apr; 26(4):292-307. PubMed ID: 8013162
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Probenecid pharmacokinetics in cystic fibrosis.
    Weber A; de Groot R; Ramsey B; Williams-Warren J; Smith A
    Dev Pharmacol Ther; 1991; 16(1):7-12. PubMed ID: 1879255
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pharmacokinetics of methicillin in patients with cystic fibrosis.
    Yaffe SJ; Gerbracht LM; Mosovich LL; Mattar ME; Danish M; Jusko WJ
    J Infect Dis; 1977 May; 135(5):828-31. PubMed ID: 404369
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Competitive inhibition of renal tubular secretion of ciprofloxacin and metabolite by probenecid.
    Landersdorfer CB; Kirkpatrick CM; Kinzig M; Bulitta JB; Holzgrabe U; Jaehde U; Reiter A; Naber KG; Rodamer M; Sörgel F
    Br J Clin Pharmacol; 2010 Feb; 69(2):167-78. PubMed ID: 20233180
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Absolute bioavailability and intracellular pharmacokinetics of azithromycin in patients with cystic fibrosis.
    Beringer P; Huynh KM; Kriengkauykiat J; Bi L; Hoem N; Louie S; Han E; Nguyen T; Hsu D; Rao PA; Shapiro B; Gill M
    Antimicrob Agents Chemother; 2005 Dec; 49(12):5013-7. PubMed ID: 16304166
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Pharmacokinetics of oral theophylline. Comparison between asthmatic and cystic fibrosis patients].
    Repetto T; Marianelli L; Valenza T; Rosselli P; Messori A
    Pediatr Med Chir; 1985; 7(6):823-5. PubMed ID: 3837249
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Retinol binding protein status in relation to ocular surface changes in patients with cystic fibrosis treated with daily vitamin A supplements.
    Mrugacz M; Tobolczyk J; Minarowska A
    Eur J Pediatr; 2005 Apr; 164(4):202-6. PubMed ID: 15789254
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Introduction to pharmacokinetics: aminoglycosides in cystic fibrosis as a prototype.
    Kearns GL; Trang JM
    J Pediatr; 1986 May; 108(5 Pt 2):847-53. PubMed ID: 3517272
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Variable theophylline clearance in cystic fibrosis.
    Taylor DM; Flowers MK
    DICP; 1991 Feb; 25(2):212. PubMed ID: 2058197
    [No Abstract]   [Full Text] [Related]  

  • 53. Comparable Bioavailability and Disposition of Pefloxacin in Patients with Cystic Fibrosis and Healthy Volunteers Assessed via Population Pharmacokinetics.
    Bulitta JB; Jiao Y; Landersdorfer CB; Sutaria DS; Tao X; Shin E; Höhl R; Holzgrabe U; Stephan U; Sörgel F
    Pharmaceutics; 2019 Jul; 11(7):. PubMed ID: 31295857
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The Significance of Bayesian Pharmacokinetics in Dosing for Critically Ill Patients: A Primer for Clinicians Using Vancomycin as an Example.
    Alnezary FS; Almutairi MS; Gonzales-Luna AJ; Thabit AK
    Antibiotics (Basel); 2023 Sep; 12(9):. PubMed ID: 37760737
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Neuropsychiatric adverse effects from CFTR modulators deserve a serious research effort.
    VanElzakker MB; Tillman EM; Yonker LM; Ratai EM; Georgiopoulos AM
    Curr Opin Pulm Med; 2023 Nov; 29(6):603-609. PubMed ID: 37655981
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pharmacokinetic Evaluation of Tacrolimus in Chinese Adult Patients during the Early Stages Post-Lung Transplantation.
    Cui YF; Pan Y; Zhu MF; Jiao Z
    J Pers Med; 2023 Apr; 13(4):. PubMed ID: 37109042
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Drug-disease interaction: Clinical consequences of inflammation on drugs action and disposition.
    Abdallah YEH; Chahal S; Jamali F; Mahmoud SH
    J Pharm Pharm Sci; 2023; 26():11137. PubMed ID: 36942294
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Plasma and cellular ivacaftor concentrations in patients with cystic fibrosis.
    Guimbellot JS; Ryan KJ; Anderson JD; Parker KL; Victoria Odom L; Rowe SM; Acosta EP
    Pediatr Pulmonol; 2022 Nov; 57(11):2745-2753. PubMed ID: 35927224
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Altered intravenous drug disposition in people living with cystic fibrosis: A meta-analysis integrating top-down and bottom-up data.
    De Sutter PJ; Van Haeverbeke M; Van Braeckel E; Van Biervliet S; Van Bocxlaer J; Vermeulen A; Gasthuys E
    CPT Pharmacometrics Syst Pharmacol; 2022 Aug; 11(8):951-966. PubMed ID: 35748042
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pharmacokinetics of Polymyxin B in Hospitalized Adults with Cystic Fibrosis.
    Crass RL; Al Naimi T; Wen B; Souza E; Murray S; Pai MP; Jia S
    Antimicrob Agents Chemother; 2021 Sep; 65(10):e0079221. PubMed ID: 34252297
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.